pharmaphorum Daily Newsletter - 22nd Jan
pharmaphorum
Industry leading publications, strategic consulting and a content-driven stakeholder engagement agency
This Wednesday, on day one of his new term, President Trump has started dismantling health legislation introduced under the Biden administration.
In other news today, the UK government has launched a ￡150 million procurement drive for artificial intelligence tools that can be used by the NHS, and Takeda’s INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.
Elsewhere, a UK alliance between data scientists, clinical researchers, and community opticians hopes to develop an AI to predict dementia during an eye test, and Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.
In our longer reads today, hear more from the JPM 2025 conference from editor-in-chief Jonah Comstock, learn what 2025 is predicted to have in store for pharma and life sciences (hint: it includes GenAI), discover more about precision psychiatry, and understand the potential benefits of self-collecting samples for HPV.
And for those who couldn’t make it to San Francisco last week, be sure to check out the pharmaphorum video interview with Vir Biotechnology’s Marianne De Backer live at JPM 2025.
All this and more on pharmaphorum.com.
News
President Trump has started dismantling health legislation introduced under the Biden administration on day one of his new term.
The UK government has launched a ￡150 million procurement drive for artificial intelligence tools that can be used by the NHS.
The INTERCEPT trial aims to validate biomarkers that could identify people at risk of Crohn's and see if treatment can prevent symptoms developing.
A UK alliance between data scientists, clinical researchers, and community opticians hopes to develop an AI to predict dementia during an eye test.
Johnson & Johnson's Spravato has become the first standalone drug to be cleared by the FDA for adults with treatment-resistant depression.
Views & Analysis
I’m back from another week in San Francisco, where as usual I heard from experts and prognosticators about their expectations for the coming year in biotech. But this year prognostication was in short supply.
2025 is going to be a year of great change. At a macro level, political and geopolitical shifts around the world will reshape relations. Regulation and deregulation may alter processes.
The mental health clinical trials market is expected to double to $4.27 billion in 2028, up from $2.15 billion in 2018, and grow more than 8% annually. Drug development in this area is costly and is marked by high failure rates and low efficacy.
Screening and early detection, as well as the introduction of a human papillomavirus (HPV) vaccine, have fuelled transformative strides in decreasing the burden of cervical cancer for women and people with a cervix.
International reliance is a mechanism whereby certain medical devices could access the UK market more quickly if they have already been approved by a comparable regulator, rather than undergoing a further full review for UK purposes only.
Podcasts & Videos
At the JP Morgan Healthcare Conference last week in San Francisco, pharmaphorum editor-in-chief Jonah Comstock spoke with Vir Biotechnology CEO Marianne De Backer, who explained a bit more about what a dual-masked T-cell engager is and why they are so promising at mitigating the toxicity of previously attempted TCEs.
At the Veeva Commercial Summit in Madrid at the end of 2024, pharmaphorum web editor Nicole Raleigh sat down with Pfizer’s head of predictive analytics, Jonathan Crowther, to discuss the role of AI in life sciences today.
In this pharmaphorum podcast, web editor Nicole Raleigh speaks with Dr Isaac Bentwich, CEO and founder of Quris.AI, about how AI could revolutionise preclinical research and accelerate the development of potentially life-saving drugs, safely.
In a new pharmaphorum podcast, web editor Nicole Raleigh speaks with Luca Quagliata, Vice President and Global Head of Medical and Scientific Affairs at Thermo Fisher Scientific, a company committed to advancing precision medicine, for a conversation on this space and a new frontier of biomarkers.
In a new pharmaphorum podcast, editor-in-chief Jonah Comstock speaks with Dr Victoria Richon, CEO of Entact Bio, a company focused on the small molecule space, with its team of scientists, entrepreneurs, drug creators, and problem solvers working together to bring new medicines to patients who currently have few options.
White Papers & Webinars
In a new white paper from Altmetric – ‘The changing landscape of journal performance measurement’ – learn how publication planners and medical affairs communications teams can leverage the new impact metrics that matter for journal selection.
Join the conversation, on Tuesday 28th January @ 10 am ET - 3 pm GMT - 4 pm CET, in our webinar sponsored by Syneos Health, entitled ‘Health Trends 2025: Reimagining What's Possible’. This forward-looking session will explore how imagination and innovation are reshaping the future of healthcare.
In a new white paper from the World Without Disease initiative, a 2024 update is provided of the endeavours and developments that occurred since inaugural discussions 2023.
A panel of experts, including from IPG Health, have shared their sector experience and wisdom in a new 60 Seconds white paper, ‘Moments of Truth: Launch’, to highlight the need to create and champion an organisational culture that underwrites a new product’s potential.
An exclusive webinar, sponsored by Trueblue, explores how life sciences organisations are leveraging the power of AI-driven strategic insights to revolutionise decision-making, enhance customer engagement, and gain a competitive edge. Available now on demand.